Popular Articles
Stretch Mark

Breakthrough Breast Cancer Research Centre Pioneering Work Leads To Patient Trial Of New Generation Cancer Drug
The drug, called olaparib, specifically targets hereditary cancer caused by faulty BRCA1 and BRCA2 genes. The small scale patient trial has shown remarkable benefit for patients with breast, ovarian and prostate cancer.
generic viagra online
Life-Saving Cardiac Rehabilitation
Coronary heart disease (CHD) is the leading cause of death worldwide and a major driver of medical and economic costs, especially among older adults. It has long been established that cardiac rehabilitation improves survival, at least in middle-aged, low- and moderate-risk white men. Now a large Brandeis University-led study published in the Journal of the American College of Cardiology reports that older cardiac patients benefit as much from cardiac rehab as their younger counterparts.
News of the day
Senators Say Supreme Court Nominee Sotomayor Committed To Rule Of Law,
Supreme Court nominee Sonia Sotomayor on Tuesday met individually with 10 senators in an initial round of closed-door meetings in preparation for her confirmation hearing, which is yet to be scheduled, the New York Times reports. Senate Judiciary Committee Chair Patrick Leahy (D-Vt.) said that during his meeting with Sotomayor she expressed her belief that ""ultimately and completely" a judge has to follow the law no matter what their upbringing has been" (Herszenhorn/Hulse, New York Times, 6/3). Sen. Dianne Feinstein (D-Calif.), who also met with Sotomayor, said that she believes that Sotomayor would not vote to overturn Roe v. Wade. Feinstein added that Sotomayor "is a woman who is well-steeped in law and well-steeped in precedent. I believe that she has a real respect for precedent and that she was not just saying that" (Isenstadt, Politico, 6/2). Senate Majority Leader Harry Reid (D-Nev.) said of Sotomayor, "We have the whole package here," adding, "We could not have anyone more qualified" (New York Times, 6/3).However, Senate Judiciary Committee ranking member Jeff Sessions (R-Ala.), who also met with Sotomayor, said that he is concerned about whether Sotomayor would be an "activist" judge who believes her role is to create policy rather than to judge matters in accordance with it. Sessions said that "the question is, what is the law? How does a judge find the law, and what approach to statutory construction do they utilize?" (Hirschfield Davis, AP/Washington Times, 6/2). According to the Times, because Republicans likely do not have the votes to use a filibuster to block Sotomayor"s confirmation, their strategy "seems to be to play for time," in the hope that "something unexpected" will surface as a threat to her confirmation. Democrats currently have 59 of the 60 votes needed to stop a filibuster, and seven Republicans voted to confirm Sotomayor to the appeals court (New York Times, 6/3). The Judicial Confirmation Network, a conservative judicial group, on Tuesday sent a letter to every senator criticizing Sotomayor"s judicial record and saying that she "challenges the belief that the law needs to be knowable and predictable." JCN Director Gary Marx said that the organization does not agree with other conservative groups that have called for a filibuster but that it supports "a long and vigorous and thorough, healthy debate" (Palmer, Roll Call, 6/2). Leahy, Sessions To Discuss Hearing Schedule Leahy said that he and Sessions will meet Wednesday to discuss a schedule for Sotomayor"s confirmation hearing, specifically with regard to whether it will come before or after the August congressional recess. Leahy said that he favors holding the hearing in July. However, Sessions and other Republicans are asking that the hearing be conducted after the break, citing the need to read through the approximately 3,000 opinions Sotomayor wrote as an appellate court judge (Friedman, CongressDaily, 6/2). Meanwhile, Sotomayor on Wednesday will meet with 10 more senators, including seven Democrats and three Republicans (Koffler, Roll Call, 6/2). Poll Shows Public SupportFifty-four percent of U.S. residents would like to see Sotomayor confirmed as a Supreme Court justice, according to a Gallup poll released Tuesday. The poll shows that 28% of those surveyed opposed the confirmation and 19% had no opinion. The poll was conducted between Friday and Sunday, questioning 1,015 adults (Silva, Los Angeles Times, 6/2).Broadcast CoverageNPR"s "All Things Considered" on Tuesday reported on Sotomayor"s meetings with senators. The segment includes comments from Leahy (Seabrook, "All Things Considered," NPR, 6/3).
Public Health

Cordex Receives Special Protocol Assessment Approval From FDA For ATPace(TM)

Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process. ATPace(TM) is a novel stable liquid formulation of adenosine 5"-triphosphate (ATP). It is being developed as a therapeutic and diagnostic drug for the management of patients with cardiac arrhythmias. ATP has been used in Europe for more than five decades as the drug of choice for the acute termination of PSVT. During this extended period of time, formulations of ATP have manifested an excellent safety and efficacy profile. Cordex intends to initiate prospective, double-blind, placebo-controlled and randomized clinical trials with its lead product ATPace(TM) in approximately 200 patients aimed at demonstrating clinical safety and efficacy sufficient to support a New Drug Application filing of ATPace(TM) for the treatment of PSVT in emergency room patients. "We are very pleased with the FDA"s decision; we believe that data to be obtained in the proposed trials would constitute sufficient evidence to support the marketing approval of ATPace(TM) for the proposed indication," commented Amir Pelleg, Ph.D., Cordex"s President and CSO. "Due to its unique mechanism of action in the heart, which involves a central vagal reflex and adenosine, the product of its rapid degradation, ATPace(TM) has the potential to be an important advance in the treatment of patients with PSVT," he added. About PSVT PSVT is an episodic, rapid, regular heart rate originating in the atria. The heart rate in PSVT can range from 150 to 250 beats per minute. There are approximately 570,000 persons with PSVT in the United States alone, with an estimated 89,000 new cases diagnosed each year. Patients with PSVT may report palpitations, pounding in the chest, chest pressure or pain, weakness, shortness of breath, or dizziness. Unless it self-terminates, PSVT patients need to seek medical intervention to terminate the arrhythmia. About Cordex Pharma, Inc. Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. ATPace(TM) is expected to enter a Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Cordex"s CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary diseases. Forward looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding the timing of ATPace(TM)"s expected entry into a pivotal Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricular tachycardia, the sufficiency of the data obtained and the anticipated results of the trial, the timing of CDP-1050"s expected commencement of a Phase 2 clinical trial for the treatment of heart failure, the expected results of the use of ATPace(TM) and the estimated PSVT market. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the data derived from the trial may not be sufficient to support marketing of approval of ATPace(TM), clinical trial for approval of ATPace(TM) and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as anticipated and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex"s most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Cordex Pharma, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):